1. Home
  2. STKS vs LCTX Comparison

STKS vs LCTX Comparison

Compare STKS & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • STKS
  • LCTX
  • Stock Information
  • Founded
  • STKS 2004
  • LCTX 1990
  • Country
  • STKS United States
  • LCTX United States
  • Employees
  • STKS N/A
  • LCTX N/A
  • Industry
  • STKS Restaurants
  • LCTX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • STKS Consumer Discretionary
  • LCTX Health Care
  • Exchange
  • STKS Nasdaq
  • LCTX Nasdaq
  • Market Cap
  • STKS 109.7M
  • LCTX 107.3M
  • IPO Year
  • STKS N/A
  • LCTX N/A
  • Fundamental
  • Price
  • STKS $2.68
  • LCTX $1.20
  • Analyst Decision
  • STKS Hold
  • LCTX Strong Buy
  • Analyst Count
  • STKS 3
  • LCTX 5
  • Target Price
  • STKS $4.50
  • LCTX $4.20
  • AVG Volume (30 Days)
  • STKS 100.1K
  • LCTX 1.7M
  • Earning Date
  • STKS 08-05-2025
  • LCTX 08-12-2025
  • Dividend Yield
  • STKS N/A
  • LCTX N/A
  • EPS Growth
  • STKS N/A
  • LCTX N/A
  • EPS
  • STKS N/A
  • LCTX N/A
  • Revenue
  • STKS $834,363,000.00
  • LCTX $10,914,000.00
  • Revenue This Year
  • STKS $27.38
  • LCTX N/A
  • Revenue Next Year
  • STKS $5.75
  • LCTX $244.95
  • P/E Ratio
  • STKS N/A
  • LCTX N/A
  • Revenue Growth
  • STKS 96.64
  • LCTX 76.43
  • 52 Week Low
  • STKS $2.37
  • LCTX $0.37
  • 52 Week High
  • STKS $5.26
  • LCTX $1.31
  • Technical
  • Relative Strength Index (RSI)
  • STKS 31.22
  • LCTX 67.31
  • Support Level
  • STKS $2.65
  • LCTX $0.97
  • Resistance Level
  • STKS $3.19
  • LCTX $1.09
  • Average True Range (ATR)
  • STKS 0.19
  • LCTX 0.09
  • MACD
  • STKS -0.01
  • LCTX 0.01
  • Stochastic Oscillator
  • STKS 9.99
  • LCTX 69.44

About STKS The ONE Group Hospitality Inc.

The One Group Hospitality Inc is a restaurant company that develops, owns and operates, manages and licenses upscale and polished casual, high-energy restaurants and lounges and provides turn-key food and beverage (F&B) services for hospitality venues, including hotels, casinos, and other high-end locations internationally. The company operates through four segments: STK, Benihana and Grill Concepts. The company generates the vast majority of its revenue from the domestic market.

About LCTX Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

Share on Social Networks: